Normalization Of Serum Vitamin Research Articles

Safety and effectiveness of vitamin D mega-dose: A systematic review.

Supplementation with high doses of vitamin D, known as mega-dose or "stoss therapy," refers to administering high doses of vitamin D by oral or intramuscular route in short periods of time. In this sense, conducting a review to organize this knowledge in a single article will generate a helpful instrument for researchers working in this area and for health professionals who use this therapeutic tool. To carry out a literature review on safety and efficacy (normalization of serum vitamin D level, and changes in the clinical picture) of vitamin D mega-dose use. This is a systematic review of the literature searching data through the electronic banks of PubMed, Scielo, and LILACS, using the following keywords: "vitamin D," "mega-dose," "stoss therapy," "cholecalciferol," in different combinations. CONSORT questionnaire was used to assess the quality of the included studies. Of the 59 articles screened for this review, 10 were included in the review, studying patients with rickets, osteoporosis, and critically ill patients. Two studies compared the exact dosage of vitamin D by different routes of administration, and three studies compared different doses by the same route. All others studied vitamin D mega-dose versus placebo. Adverse effects were observed through the presence of hypercalcemia/hypercalciuria. Serum vitamin D levels were normalized between 70 and 100% of patients, and adverse effects ranged between 1.9 and 18.5%. The study demonstrated that vitamin D mega-dose therapy is effective in normalizing serum vitamin levels, and the toxicity assessed through adverse effects was low, with no expressive clinical significance. Despite this, there is still a need for further studies in the area to confirm the results found.

NORMALIZATION OF SERUM VITAMIN D IMPROVES SEMEN MOTILITY PARAMETERS IN PATIENTS WITH IDIOPATHIC MALE INFERTILITY.

Idiopathic male infertility is evident in half of infertile males. Vitamin D receptors are expressed throughout male reproductive tract, including spermatozoa, promoting motility. Epidemiological studies revealed the positive association between serum vitamin D and semen quality. However, there are no clinical studies examining the differential role of vitamin D in idiopathic male infertility. 1) To investigate the association between vitamin D deficiency and idiopathic male infertility, and 2) To determine whether vitamin D deficient males would show restoration of semen quality parameters upon supplementation with vitamin D. This was a year-long case-control study from November 2015 to November 2016. A therapeutic intervention cohort for 2 months was also performed. 117 Jordanian males were enrolled. Following a clinical evaluation by a urologist, baseline serum vitamin D and semen fluid analyses were collected. Participants were stratified into 3 groups: controls (n=30), idiopathic infertility (n=67), and secondary infertility (n=20). Idiopathic infertility patients with low vitamin D (n= 45) were supplemented with oral vitamin D, 5000 IU, once daily for two months. Thereafter, serum vitamin D and semen fluid analyses were reassessed (n= 34; 11 patients were lost to follow up). Vitamin D was significantly lower in patients with idiopathic infertility than in both controls and men with secondary infertility. Significant improvement of progressive and total sperm motility was observed after vitamin D treatment. Vitamin D correlated significantly with semen quality in the study population. However, no correlation was found between vitamin D and any of the semen quality parameters in the idiopathic infertility group. Vitamin D supplementation improves sperm motility in idiopathic male infertility patients with low vitamin D. Larger and longer clinical trials are warranted to validate the use of vitamin D in these cases.

КОМПЛЕКСНІ ПРЕПАРАТИ НА ОСНОВІ НАНОБІОМАТЕРІАЛІВ, ПЕРСПЕКТИВИ ВИКОРИСТАННЯ У РЕПРОДУКЦІЇ ОВЕЦЬ ТА КІЗ

A complex preparations «Kahadin + OV», «Kaplaestrol + OV», «Karafest + OV» and «Karafand + OV», which have antioxidant, anti-hypoxic and membranoprotective properties thanks to nanobiomaterials.Were tested drug «Karafest + OV Zn», at doses of justification which came out of the daily needs of animals in the components of the drug, which for sheep and goats in the last 7-8 weeks of pregnancy (per animal), carotene – 0.28–0.5 mg/kg, or 12–26 mg, phytoestrogens – 0,0175 mg/kg or 0.61-1.22 mg, zinc – 1-1.08 mg/kg, or 54-70 mg.The content of substances in 1 ml «Karafest + OV Zn» according to the technical specifications are: carotene - 10 mg (1,2-2,6 ml), phytoestrogens - 1 mg (0.6-1.2 ml), zinc carbonate – 2 mg, ortovanadatе europium activated gadolinium – 0.00015 mg.The final dosage was determined by the scheme – 0.35–2.1 ml/animal оr 0.01–0.03 ml/kg body weight/day.The drug «Karafest + OV Zn» asked orally with food daily for a month to projected pregnancy (140 days of pregnancy).The positive effect of the drug «Karafest + OV Zn» at the homeostasis parameters in sheep, including normalization of serum vitamin A, zinc and total protein; prooxidative-antioxidant system containing serum – malondialdehyde, catalase, superoxide dismutase and erythrocyte – malondialdehyde, catalase, restored glutathione and oxidative-antioxidant value; system state oxygen metabolism – the number of red blood cells and hemoglobin concentration of 2.3-dyphosphoglyceratis.Thus, the use of the drug «Karafest + OV Zn» increased content in blood serum, vitamin A (by 16.2%), zinc (by 23,4%), total protein (by 11.5%), malondialdehyde (by 17.5%), catalase (by 24.7%), superoxide dismutase (by 17.9%); in erythrocytes: (by 24.4%), catalase (by 23.9 %) and reduced glutathione (by 18.2%) and hemoglobin (by 23.5 %), the actual number of red blood cells (by 21.8%), the concentration of 2,3-dyphosphoglyceratis (by 22.2%) and normalized prooxidant-antioxidant ratio.

Vitamin D, determinant of bone and extrabone health. Importance of vitamin D supplementation in milk and dairy products

Vitamin D is obtained mainly from ultraviolet irradiation of 7-dehydrocholesterol in the skin to form cholecalciferol (vitamin D3), and minimally from diet, unless vitamin D fortified food is taken, mainly enriched milk. In some countries, vitamin D is added to diet as ergocalciferol (vitamin D2). In the liver, vitamin D3 is hydroxylated to form 25-hydroxyvitamin D3 (marker of body nutritional status of vitamin D). Subsequently, in the kidney, 25OHD3 is hydroxylated to form 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). By VDR stimulation, (1,25)OH)2D3 controls calcium homeostasis and bone health and, what is more, many other cells and tissues including skin, muscle, cardiovascular and immune systems as well as glucose homeostasis. Thus, about 3% of the human genome is regulated by this hormone. Association and recent intervention studies describe beneficial effects on bone, cardiovascular disease, hypertension, diabetes mellitus type 2,colorectal cancer, breast cancer, multiple sclerosis, immune function inflammation etc. A minimum target for public health should be to achieve serum 25OHD levels above 20 ng/ml to ensure optimum status for bone health. However, levels above 30 ng/ml should be reached to achieve other health goals. Paradoxically, inadequacy (or even deficiency) in vitamin D levels is highly prevalent in children and youth in Spain. This deficit persists in adults, as well as in postmenopausal women (osteoporotic or not) and the elderly (especially amongst those institutionalized). Seasonal variation barely normalizes serum 25OHD levels after summer-autumn. Treated postmenopausal osteoporotic women also show high prevalence of inadequate levels of vitamin D, a major contributor to antiresortive treatments failure. A normalization of serum vitamin D enables diet to provide the calcium necessary to achieve a good bone health and an adequate response to antiresortive drugs. Given the difficulty to get adequate levels of vitamin D by UV irradiation and diet, a proper supplementation of milk with vitamin D is an attractive chance and a challenge for Public Health of Spain and the European Union. It has provided excellent results in the US, Canada, Northern Europe Countries, etc.

SAT0476 Vitamin D Supplementation in Liver Transplant Patients

BackgroundLiver transplant patients are at risk of developing osteoporosis and vitamin D deficiency. This deficit can be correlated with an increase in the rate of bone destruction and a decrease...

Serum Vitamin D Levels in Orthopaedic Trauma Patients Living in the Northwestern United States

To determine the incidence of vitamin D deficiency in orthopaedic trauma patients undergoing fracture surgery living in the Northwest United States. Retrospective observational cohort study. Level 2 trauma center. Two cohorts of patients undergoing fracture repair surgery during a 3-month period in winter and summer had serum vitamin D levels drawn at the time of surgery. One hundred three patients were reviewed in the winter cohort and 98 in the summer cohort. Serum 25(OH) vitamin D levels of patients undergoing fracture repair surgery. Normal levels of vitamin D were considered to be between 32 and 80 ng/mL. Most patients in both cohorts were vitamin D insufficient. The average level for the winter cohort was 26.4 ng/mL, which was significantly lower than the average level for the summer cohort, 29.8 ng/mL (P = 0.03). A high incidence of vitamin D insufficiency and deficiency likely exists across all age groups in orthopaedic trauma patients living in the Northwest United States and regions with similarly northern latitude. Further study is required to confirm improved fracture healing with normalization of serum vitamin D levels. Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: clinical and muscle biopsy findings and treatment with alpha-tocopherol.

We have studied four children (ages 6 to 17 years) with chronic cholestasis who developed a slowly progressive neuromuscular disease characterized by ataxia, dysmetria, areflexia, loss of vibratory sensation, and a variable ophthalmoplegia. Serum vitamin E concentrations were low in all patients prior to treatment (0.17-2.0 mg/g cholesterol, normal greater than 3 mg/g). Muscle histochemical studies showed prominent yellow autofluorescence, basophilic cytoplasmic inclusions which stain with esterase and acid phosphatase, and occasional necrotic fibers. Ultrastructural findings consisted of increased number and size of membrane-bound dense bodies (lysosomes), membranous whorls, and autophagic vacuoles. Intramuscular injections of all-rac-alpha-tocopherol (0.55-1.42 mg/kg per 24 hours based on individualized pharmacokinetic data) were required in three patients to achieve normal serum vitamin E values. High-dose (32 mg/kg per 24 hours) oral supplementation was effective in one patient. After normalization of serum vitamin E concentrations for 12 to 20 months, the neurologic disease has improved in all four patients.

Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: Diagnosis and treatment with alpha tocopherol

We have studied four children (ages 6 to 17 years) with chronic cholestasis who developed a slowly progressive neuromuscular disease characterized by ataxia, dysmetria, areflexia, loss of vibratory sensation, and a variable ophthalmoplegia. Serum vitamin E concentration were low in all patients prior to treatment. Muscle histochemical studies in all four patients showed autofluorescent basophilic esterase and acid phosphatase-positive cytoplasmic inclusions and occasional necrotic fibers. These distinctive muscle changes are similar to those described in vitamin E-deficient animals. Intramuscular injections of alpha tocopherol were required in three patients to achieve normal serum vitamin E values. High-dose oral supplementation was effective in one patient. After normalization of serum vitamin E concentrations for six to 14 months, the neurologic disease has improved in all four patients.

Vitamin A and zinc therapy in primary biliary cirrhosis

Eleven patients with primary biliary cirrhosis were surveyed for evidence of vitamin A and zinc deficiencies. Vitamin A deficiency manifested as a low serum vitamin A concentration and abnormal dark adaptation was present in 9 of the 11 patients. A low serum zinc level was present in four patients who were also vitamin A deficient. All seven patients who received p.o. vitamin A therapy with 25,000 to 50,000 units per day for 4 to 12 weeks achieved normal vitamin A levels. Normalization of serum vitamin A was associated with significant improvement in dark adaptation (p less than 0.01). In three patients, normalization of serum vitamin A level did not correct the abnormal dark adaptation. These three patients also had decreased serum zinc levels and dark adaptation abnormalities were corrected following p.o zinc supplementation. These studies suggest high dose and long term p.o. vitamin A and zinc therapy may be required to correct abnormalities in dark adaptation in patients with primary biliary cirrhosis.